AREXVY Respiratory Syncytial Virus Vaccine Recombinant, Adjuvanted
                
                
                
                    Highlights: 
- Overall effectiveness in protecting against lower respiratory tract disease (LRTD) caused by RSV - 82.6%
- Efficacy in protection against RSV LRTD in patients with at least 1 comorbidity of interest* - 94.6%
*Comorbidities of interest: COPD, asthma, any chronic respiratory/pulmonary disease, chronic heart failure, diabetes mellitus, advanced liver or renal disease
 
How:
- Intramuscular Injection
- Single-dose administration
 
Designated Quality HealthCare Medical Centres:
Click here for more details.
Scan & Book appointment via QHMS mobile app or WhatsApp 8301-8301
 
      
                
                        
                            Recommended for
                            
                                Individuals aged 60 or above and 50-59 years of age who are at increased risk^. High-risk individuals who have: chronic pulmonary disease, chronic cardiovascular disease, diabetes, chronic liver disease, or chronic kidney disease.